Swedish biotech company Mercodia has announced a strategic collaboration with Chongqing Zhongyuan Biotechnology Co in China.

In connection with the announcement of this collaboration, a Zhongyuan-Mercodia Diabetes Science and Technology Centre was established in Chongqing, China. This will allow the companies to combine their know-how on a new platform that fits the clinical requirements of automation.

“The collaboration between Mercodia and Zhongyuan is a very good match, since our company values and focus areas fit each other very well. We are also very happy about this expansion on the Chinese market, since our company vision is to provide high quality immunoassays to researchers around the world to improve human health. We are also proud to be part of advancing the science and technology in diabetes through our joint research center with Zhongyuan Biotech.” says Mona Österberg, president of Mercodia.

Dr. Li Minyou, the chairman of Zhongyuan Biotech comments, “We are extremely pleased to be associated with a great company like Mercodia. Our cooperation will accelerate the development of new and high quality products in the field of clinical diagnosis of diabetes to the benefit of over 100 million diabetic patients in China”.

The collaboration was announced at a ceremony at the Sofitel Hotel, Chongqing, China on the 22nd of February, 2014. The ceremony was covered by Chinese media and attended by Chinese government officials.

Source: Uppsala Bio